Page 43 - Read Online

Page 10 of 10 Carr. Hepatoma Res 2019;5:3 I http://dx.doi.org/10.20517/2394-5079.2018.113

hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
38. Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, et al. Ramucirumab as second-line treatment in patients with
advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised
phase III REACH study. Eur J Cancer 2017;81:17-25.
39. Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, et al. Ramucirumab as second-line treatment in patients with advanced
hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol 2017;52:494-503.
40. Carr BI, Guerra V. Hepatocellular carcinoma extrahepatic metastasis in relation to tumor size and alkaline phosphatase levels.
Oncology 2016;90:136-42.
41. Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular
invasion or metastatic disease: a systematic review and met-analysis. Hepatology 2018;67:422-35.
42. Han K, Kim JH, Ko GY, Gwon DI, Sung KB. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a
comprehensive review. World J Gastroenterology 2016;22:407-16.
43. Mazzaferro V, Sposito C, Bhoori S, Romito R, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular
carcinoma: a phase 2 study. Hepatology 2013;57:1826-37.
44. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD Guidelines for the treatment of hepatocellular carcinoma.
Hepatology 2018;67:358-80.
45. Akkiz H, Carr BI, Kuran S, Karaoğullarından Ü, Üsküdar O, et al. Macroscopic portal vein thrombosis in HCC patients. Canadian J
Gastroenterol Hepatol 2018; doi: 10.1155/2018/3120185.
46. Cheng S, Chen M, Cai J; National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor
Thrombus.. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor
thrombus: 2016 edition. Oncotarget 2017;8:8867-76.
47. Wang K, Guo WX, Chen MS, Mao YL, Sun BC, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor
thrombus: a large-scale, multicentre, propensity matching score analysis. Medicine (Baltimore) 2016;95:e3015.
48. Liu L, Chen H, Wang M, Zhao Y, Cai G, et al. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review
and meta-analysis. PLoS One2014;9:e91124.
49. Zhang X, Wang K, Wang M, Yang G, Ye X, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for
hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget 2017;8:29416-27.
50. Carr BI, Pancoska P, Giannini EG, Farinati F, Ciccarese F, et al. Identification of two clinical hepatocellular carcinoma patient
phenotypes from results of standard screening parameters. Semin Oncol 2014;41:406-14.
51. Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, et al. Tivantinib for second-line treatment of MET-high,
advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol
2018;19:682-93.